Trial Profile
A Phase 2, Single-center, Randomized, Double-Blinded, Placebo-Controlled Study on the Efficacy of Daikenchuto (TU 100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2017
Price :
$35
*
At a glance
- Drugs TU 100 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Tsumura
- 25 Apr 2016 Status changed from recruiting to completed.
- 19 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
- 19 May 2015 Planned primary completion date changed from 1 May 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.